[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-001", "question": "A 14-year-old boy with juvenile idiopathic arthritis presents with acute onset of fever, rash, and joint swelling after starting etanercept therapy. Laboratory findings include elevated ferritin, pancytopenia, and hypertriglyceridemia. What is the most appropriate next step in management?", "options": ["Discontinue etanercept and initiate high-dose corticosteroids", "Administer intravenous immunoglobulin", "Start rituximab infusion", "Perform bone marrow biopsy immediately", "Initiate broad-spectrum antibiotics"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with macrophage activation syndrome (MAS), a life-threatening complication in rheumatic diseases like juvenile idiopathic arthritis, often triggered by biologic agents such as etanercept. Discontinuing the offending agent and starting high-dose corticosteroids is the initial management to control the cytokine storm. Bone marrow biopsy may confirm hemophagocytosis but is not the immediate next step, and antibiotics are inappropriate without evidence of infection.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old with JIA on etanercept presenting with fever, rash, joint swelling, elevated ferritin, pancytopenia, and hypertriglyceridemia—classic features of macrophage activation syndrome (MAS). Key discriminating findings include: (1) temporal association with etanercept initiation, (2) hyperferritinemia, (3) cytopenias, (4) hypertriglyceridemia—all meeting diagnostic criteria for MAS/secondary HLH. The keyed answer (A) correctly identifies immediate discontinuation of the triggering biologic plus high-dose corticosteroids as first-line therapy for MAS, consistent with current rheumatology guidelines. Alternative analysis: (B) IVIG may be adjunctive but is not first-line for MAS; (C) rituximab is reserved for refractory cases; (D) bone marrow biopsy confirms hemophagocytosis but delays urgent treatment; (E) antibiotics are inappropriate without infection evidence. The stem provides sufficient detail to distinguish MAS from infection or other complications. Medical accuracy is excellent—management aligns with ACR/EULAR MAS guidelines emphasizing early corticosteroids and trigger removal. No logical flaws or ambiguity exist. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old with JIA on etanercept presenting with fever, rash, joint swelling, elevated ferritin, pancytopenia, and hypertriglyceridemia—classic features of macrophage activation syndrome (MAS). Key discriminating findings include: (1) temporal association with etanercept initiation, (2) hyperferritinemia, (3) cytopenias, (4) hypertriglyceridemia—all meeting diagnostic criteria for MAS/secondary HLH. The keyed answer (A) correctly identifies immediate discontinuation of the triggering biologic plus high-dose corticosteroids as first-line therapy for MAS, consistent with current rheumatology guidelines. Alternative analysis: (B) IVIG may be adjunctive but is not first-line for MAS; (C) rituximab is reserved for refractory cases; (D) bone marrow biopsy confirms hemophagocytosis but delays urgent treatment; (E) antibiotics are inappropriate without infection evidence. The stem provides sufficient detail to distinguish MAS from infection or other complications. Medical accuracy is excellent—management aligns with ACR/EULAR MAS guidelines emphasizing early corticosteroids and trigger removal. No logical flaws or ambiguity exist. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-002", "question": "A 65-year-old man with hypertrophic cardiomyopathy develops sudden syncope during exercise. Echocardiography shows left ventricular outflow tract obstruction with a gradient of 80 mmHg. Despite beta-blocker therapy, symptoms persist. What is the most definitive management option?", "options": ["Surgical septal myectomy", "Alcohol septal ablation", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Verapamil initiation"], "answer": "A", "answer_index": 0, "explanation": "Surgical septal myectomy is the gold standard for symptomatic hypertrophic cardiomyopathy with severe outflow tract obstruction refractory to medical therapy, offering superior long-term outcomes in experienced centers. Alcohol septal ablation is an alternative but carries risks like heart block and is less effective in younger patients. ICD placement addresses arrhythmic risk but not the obstruction itself.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) presenting with exertional syncope, severe LVOT obstruction (gradient 80 mmHg), and symptoms refractory to beta-blocker therapy. Key discriminating findings: (1) severe symptomatic LVOT obstruction despite medical therapy, (2) high gradient indicating hemodynamically significant obstruction, (3) exercise-induced syncope suggesting inadequate cardiac output. The question asks for the most definitive management option. Surgical septal myectomy (A) is the gold standard for symptomatic HOCM with severe obstruction refractory to medical therapy, offering superior long-term outcomes and durability. Alcohol septal ablation (B) is an alternative but considered less definitive, with higher complication rates (heart block) and less predictable outcomes. ICD placement (C) addresses sudden cardiac death risk but does not treat the obstruction causing symptoms. Dual-chamber pacing (D) has limited efficacy for gradient reduction. Verapamil (E) is medical therapy already failed by beta-blockers. The keyed answer is medically accurate and represents the definitive treatment per current guidelines. No logical flaws exist; the stem provides sufficient information for a unique best answer. Minimal fix: None needed; item is valid.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) presenting with exertional syncope, severe LVOT obstruction (gradient 80 mmHg), and symptoms refractory to beta-blocker therapy. Key discriminating findings: (1) severe symptomatic LVOT obstruction despite medical therapy, (2) high gradient indicating hemodynamically significant obstruction, (3) exercise-induced syncope suggesting inadequate cardiac output. The question asks for the most definitive management option. Surgical septal myectomy (A) is the gold standard for symptomatic HOCM with severe obstruction refractory to medical therapy, offering superior long-term outcomes and durability. Alcohol septal ablation (B) is an alternative but considered less definitive, with higher complication rates (heart block) and less predictable outcomes. ICD placement (C) addresses sudden cardiac death risk but does not treat the obstruction causing symptoms. Dual-chamber pacing (D) has limited efficacy for gradient reduction. Verapamil (E) is medical therapy already failed by beta-blockers. The keyed answer is medically accurate and represents the definitive treatment per current guidelines. No logical flaws exist; the stem provides sufficient information for a unique best answer. Minimal fix: None needed; item is valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-003", "question": "A term neonate develops respiratory distress and hypotension shortly after birth. Physical exam reveals hepatomegaly and poor perfusion. Echocardiogram shows dilated cardiomyopathy. Maternal history includes untreated systemic lupus erythematosus. What is the underlying mechanism?", "options": ["Transplacental passage of anti-Ro/SSA antibodies causing atrioventricular block", "Congenital viral infection leading to myocarditis", "Inborn error of metabolism affecting cardiac function", "Asphyxia-induced hypoxic cardiomyopathy", "Genetic mutation in sarcomeric proteins"], "answer": "A", "answer_index": 0, "explanation": "Neonatal lupus from maternal anti-Ro/SSA antibodies can cause complete heart block and cardiomyopathy, leading to heart failure in the newborn. This is distinct from viral myocarditis, which typically presents later and lacks the maternal autoimmune history. Metabolic or genetic causes are less likely without additional syndromic features.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer does not match the clinical presentation. Key stem clues: term neonate with respiratory distress, hypotension, hepatomegaly, poor perfusion, and dilated cardiomyopathy on echo; maternal untreated SLE. The question asks for the underlying mechanism of this presentation. Option A describes anti-Ro/SSA antibodies causing atrioventricular block, which is the classic manifestation of neonatal lupus erythematosus (congenital heart block). However, the vignette explicitly describes dilated cardiomyopathy, NOT heart block. While neonatal lupus can rarely cause cardiomyopathy, the mechanism is NOT through AV block as stated in option A – AV block and dilated cardiomyopathy are distinct cardiac manifestations. The echo finding of dilated cardiomyopathy directly contradicts option A's mechanism of AV block. Option B (viral myocarditis) could explain dilated cardiomyopathy in a neonate, though the maternal SLE history is a red herring. The item conflates two different cardiac manifestations of neonatal lupus. Minimal fix: Either change the echo finding to 'complete heart block' to match option A, or change option A to describe the actual mechanism of lupus-associated cardiomyopathy (myocardial inflammation/fibrosis from maternal antibodies).\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer does not match the clinical presentation. Key stem clues: term neonate with respiratory distress, hypotension, hepatomegaly, poor perfusion, and dilated cardiomyopathy on echo; maternal untreated SLE. The question asks for the underlying mechanism of this presentation. Option A describes anti-Ro/SSA antibodies causing atrioventricular block, which is the classic manifestation of neonatal lupus erythematosus (congenital heart block). However, the vignette explicitly describes dilated cardiomyopathy, NOT heart block. While neonatal lupus can rarely cause cardiomyopathy, the mechanism is NOT through AV block as stated in option A – AV block and dilated cardiomyopathy are distinct cardiac manifestations. The echo finding of dilated cardiomyopathy directly contradicts option A's mechanism of AV block. Option B (viral myocarditis) could explain dilated cardiomyopathy in a neonate, though the maternal SLE history is a red herring. The item conflates two different cardiac manifestations of neonatal lupus. Minimal fix: Either change the echo finding to 'complete heart block' to match option A, or change option A to describe the actual mechanism of lupus-associated cardiomyopathy (myocardial inflammation/fibrosis from maternal antibodies).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-004", "question": "A 28-year-old woman at 32 weeks gestation presents with severe preeclampsia and acute dyspnea. Echocardiography reveals peripartum cardiomyopathy with ejection fraction of 30%. What is the most critical intervention to improve maternal outcomes?", "options": ["Immediate delivery via cesarean section", "Initiate bromocriptine to suppress prolactin", "Administer intravenous furosemide and vasodilators", "Start anticoagulation with low-molecular-weight heparin", "Perform urgent cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "Bromocriptine inhibits prolactin, which is implicated in the pathogenesis of peripartum cardiomyopathy, and has shown benefit in improving left ventricular function when added to standard heart failure therapy. Immediate delivery may be necessary for preeclampsia but does not directly address cardiomyopathy. Diuretics and vasodilators manage symptoms but are not disease-modifying in this context.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. The stem describes a 28-year-old at 32 weeks with severe preeclampsia AND peripartum cardiomyopathy with acute dyspnea and EF 30%. The question asks for the \\\"most critical intervention to improve maternal outcomes.\\\" Key discriminating findings: severe preeclampsia at 32 weeks (definitive treatment is delivery), acute decompensated heart failure (dyspnea, EF 30%), dual life-threatening conditions. The keyed answer (B, bromocriptine) is based on emerging evidence for PPCM but remains investigational and is NOT standard first-line therapy. The most critical immediate intervention for severe preeclampsia with maternal instability is delivery (A), which addresses the preeclampsia definitively and may improve cardiac function by removing the hemodynamic burden of pregnancy. Standard PPCM management includes diuretics/vasodilators (C) for acute decompensation. Bromocriptine is adjunctive at best and not universally recommended as first-line. The item conflates \\\"most critical\\\" with \\\"disease-modifying for PPCM\\\" while ignoring that severe preeclampsia itself requires delivery. Medical accuracy issue: overstates bromocriptine's role as \\\"most critical\\\" when delivery addresses both conditions. Minimal fix: Either remove severe preeclampsia from the stem or rephrase to ask specifically about PPCM-targeted therapy after stabilization.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. The stem describes a 28-year-old at 32 weeks with severe preeclampsia AND peripartum cardiomyopathy with acute dyspnea and EF 30%. The question asks for the \"most critical intervention to improve maternal outcomes.\" Key discriminating findings: severe preeclampsia at 32 weeks (definitive treatment is delivery), acute decompensated heart failure (dyspnea, EF 30%), dual life-threatening conditions. The keyed answer (B, bromocriptine) is based on emerging evidence for PPCM but remains investigational and is NOT standard first-line therapy. The most critical immediate intervention for severe preeclampsia with maternal instability is delivery (A), which addresses the preeclampsia definitively and may improve cardiac function by removing the hemodynamic burden of pregnancy. Standard PPCM management includes diuretics/vasodilators (C) for acute decompensation. Bromocriptine is adjunctive at best and not universally recommended as first-line. The item conflates \"most critical\" with \"disease-modifying for PPCM\" while ignoring that severe preeclampsia itself requires delivery. Medical accuracy issue: overstates bromocriptine's role as \"most critical\" when delivery addresses both conditions. Minimal fix: Either remove severe preeclampsia from the stem or rephrase to ask specifically about PPCM-targeted therapy after stabilization.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-005", "question": "In the ICU, a 55-year-old patient with septic shock on vasopressors develops acute kidney injury and metabolic acidosis. Despite fluid resuscitation, oliguria persists. Continuous renal replacement therapy is initiated. What is the most appropriate modality to optimize hemodynamic stability?", "options": ["Continuous venovenous hemodiafiltration with citrate anticoagulation", "Intermittent hemodialysis with bicarbonate buffer", "Sustained low-efficiency dialysis", "Peritoneal dialysis", "Continuous venovenous hemofiltration alone"], "answer": "A", "answer_index": 0, "explanation": "Continuous venovenous hemodiafiltration (CVVHDF) provides both convective and diffusive clearance, making it ideal for septic shock with acidosis, and citrate anticoagulation minimizes clotting while providing regional effects. Intermittent hemodialysis can cause hemodynamic instability in critically ill patients. Peritoneal dialysis is less efficient for rapid toxin removal in this setting.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a hemodynamically unstable ICU patient (septic shock on vasopressors) with AKI, metabolic acidosis, and persistent oliguria requiring CRRT. The question explicitly asks for the modality that optimizes hemodynamic stability. Key discriminating findings: (1) septic shock on vasopressors (hemodynamically unstable), (2) AKI with oliguria, (3) metabolic acidosis. CVVHDF (option A) is the best answer because continuous therapies are superior to intermittent modalities for hemodynamic stability in shock states, and citrate anticoagulation avoids systemic heparin effects while providing regional anticoagulation. Option B (intermittent HD) causes rapid fluid/solute shifts leading to hypotension in unstable patients. Option C (SLED) is intermediate but still less gentle than CVVHDF. Option D (peritoneal dialysis) is inadequate for acute management in ICU septic shock. Option E (CVVH alone) lacks the diffusive component for optimal acidosis correction. The keyed answer is medically accurate and uniquely defensible. No logical flaws or medical inaccuracies detected. The item correctly tests knowledge of CRRT modality selection in hemodynamically unstable patients. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a hemodynamically unstable ICU patient (septic shock on vasopressors) with AKI, metabolic acidosis, and persistent oliguria requiring CRRT. The question explicitly asks for the modality that optimizes hemodynamic stability. Key discriminating findings: (1) septic shock on vasopressors (hemodynamically unstable), (2) AKI with oliguria, (3) metabolic acidosis. CVVHDF (option A) is the best answer because continuous therapies are superior to intermittent modalities for hemodynamic stability in shock states, and citrate anticoagulation avoids systemic heparin effects while providing regional anticoagulation. Option B (intermittent HD) causes rapid fluid/solute shifts leading to hypotension in unstable patients. Option C (SLED) is intermediate but still less gentle than CVVHDF. Option D (peritoneal dialysis) is inadequate for acute management in ICU septic shock. Option E (CVVH alone) lacks the diffusive component for optimal acidosis correction. The keyed answer is medically accurate and uniquely defensible. No logical flaws or medical inaccuracies detected. The item correctly tests knowledge of CRRT modality selection in hemodynamically unstable patients. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-006", "question": "A 45-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and dry cough. High-resolution CT shows subpleural reticular opacities and traction bronchiectasis. Pulmonary function tests reveal restrictive pattern. What is the most likely diagnosis?", "options": ["Methotrexate-induced interstitial lung disease", "Rheumatoid arthritis-associated usual interstitial pneumonia", "Hypersensitivity pneumonitis from environmental exposure", "Non-specific interstitial pneumonia", "Cryptogenic organizing pneumonia"], "answer": "B", "answer_index": 1, "explanation": "Rheumatoid arthritis can cause interstitial lung disease with a usual interstitial pneumonia pattern, which is more common than methotrexate toxicity in long-term users. Methotrexate-induced ILD typically presents acutely and improves upon discontinuation, unlike this progressive course. Hypersensitivity pneumonitis would show upper lobe predominance and different triggers.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with RA on methotrexate presenting with progressive dyspnea, dry cough, HRCT showing subpleural reticular opacities with traction bronchiectasis, and restrictive PFTs—all consistent with UIP pattern. Both options A (MTX-induced ILD) and B (RA-associated UIP) are defensible. The rationale claims MTX-ILD is typically acute, but MTX can cause chronic progressive ILD indistinguishable from RA-ILD. Without critical discriminators (duration of MTX use, temporal relationship to drug initiation, BAL findings, or biopsy), both etiologies remain plausible. The stem lacks: (1) MTX duration/dose, (2) timing of symptom onset relative to MTX start, (3) whether MTX was discontinued with response assessment. RA-ILD and MTX-ILD can both present with UIP pattern and progressive course. The explanation's assertion that MTX-ILD is 'typically acute' oversimplifies—chronic MTX pneumonitis exists. Medical accuracy issue: The teaching point conflates clinical patterns that overlap significantly without providing discriminating features. Minimal fix: Add 'Patient has been on methotrexate for 8 years with symptom onset over the past 6 months' to favor chronic RA-ILD over drug toxicity, or add 'Symptoms began 6 weeks after starting methotrexate' to favor MTX-induced disease.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with RA on methotrexate presenting with progressive dyspnea, dry cough, HRCT showing subpleural reticular opacities with traction bronchiectasis, and restrictive PFTs—all consistent with UIP pattern. Both options A (MTX-induced ILD) and B (RA-associated UIP) are defensible. The rationale claims MTX-ILD is typically acute, but MTX can cause chronic progressive ILD indistinguishable from RA-ILD. Without critical discriminators (duration of MTX use, temporal relationship to drug initiation, BAL findings, or biopsy), both etiologies remain plausible. The stem lacks: (1) MTX duration/dose, (2) timing of symptom onset relative to MTX start, (3) whether MTX was discontinued with response assessment. RA-ILD and MTX-ILD can both present with UIP pattern and progressive course. The explanation's assertion that MTX-ILD is 'typically acute' oversimplifies—chronic MTX pneumonitis exists. Medical accuracy issue: The teaching point conflates clinical patterns that overlap significantly without providing discriminating features. Minimal fix: Add 'Patient has been on methotrexate for 8 years with symptom onset over the past 6 months' to favor chronic RA-ILD over drug toxicity, or add 'Symptoms began 6 weeks after starting methotrexate' to favor MTX-induced disease.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-007", "question": "A 2-year-old child with hypoplastic left heart syndrome post-Norwood procedure presents with cyanosis and metabolic acidosis. Echocardiography shows right ventricular dysfunction and tricuspid regurgitation. What is the most appropriate pharmacologic intervention?", "options": ["Milrinone infusion for inotropic support", "Prostaglandin E1 to maintain ductal patency", "Sildenafil for pulmonary hypertension", "Digoxin for rate control", "Epinephrine bolus for hypotension"], "answer": "A", "answer_index": 0, "explanation": "Milrinone provides inotropic support and pulmonary vasodilation, crucial for right ventricular failure in single-ventricle physiology after Norwood. Prostaglandin E1 is used preoperatively but not post-Norwood. Sildenafil targets pulmonary hypertension but lacks the inotropic effect needed here.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a post-Norwood patient (single-ventricle physiology) with cyanosis, metabolic acidosis, RV dysfunction, and tricuspid regurgitation—indicating acute RV failure with low cardiac output. Key discriminating findings: post-Norwood status (systemic RV), RV dysfunction, TR, and metabolic acidosis (tissue hypoperfusion). The most appropriate intervention requires both inotropic support and afterload reduction. Option A (Milrinone): Correct—provides inotropic support via phosphodiesterase-3 inhibition plus systemic/pulmonary vasodilation, ideal for RV failure in single-ventricle physiology. Option B (PGE1): Incorrect—maintains ductal patency pre-operatively; post-Norwood patients have surgical shunts (modified BT or RV-PA conduit), making PGE1 unnecessary and potentially harmful. Option C (Sildenafil): Addresses pulmonary vasodilation but lacks inotropic effect needed for acute RV failure. Option D (Digoxin): Too slow onset for acute decompensation; minimal role in acute RV failure. Option E (Epinephrine bolus): Increases afterload and may worsen RV function; continuous infusion might be considered but bolus is inappropriate. The stem provides sufficient detail to identify milrinone as uniquely addressing both inotropic need and vascular resistance. Medical accuracy is high; milrinone is standard for post-Norwood RV failure. Minimal fix: None needed; item is valid.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a post-Norwood patient (single-ventricle physiology) with cyanosis, metabolic acidosis, RV dysfunction, and tricuspid regurgitation—indicating acute RV failure with low cardiac output. Key discriminating findings: post-Norwood status (systemic RV), RV dysfunction, TR, and metabolic acidosis (tissue hypoperfusion). The most appropriate intervention requires both inotropic support and afterload reduction. Option A (Milrinone): Correct—provides inotropic support via phosphodiesterase-3 inhibition plus systemic/pulmonary vasodilation, ideal for RV failure in single-ventricle physiology. Option B (PGE1): Incorrect—maintains ductal patency pre-operatively; post-Norwood patients have surgical shunts (modified BT or RV-PA conduit), making PGE1 unnecessary and potentially harmful. Option C (Sildenafil): Addresses pulmonary vasodilation but lacks inotropic effect needed for acute RV failure. Option D (Digoxin): Too slow onset for acute decompensation; minimal role in acute RV failure. Option E (Epinephrine bolus): Increases afterload and may worsen RV function; continuous infusion might be considered but bolus is inappropriate. The stem provides sufficient detail to identify milrinone as uniquely addressing both inotropic need and vascular resistance. Medical accuracy is high; milrinone is standard for post-Norwood RV failure. Minimal fix: None needed; item is valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-008", "question": "A 70-year-old man with atrial fibrillation on anticoagulation develops acute chest pain and hypotension. Coronary angiography shows no obstructive disease, but left ventriculography reveals apical ballooning. What is the underlying pathophysiology?", "options": ["Catecholamine surge leading to transient myocardial stunning", "Spontaneous coronary artery dissection", "Myocarditis from viral infection", "Embolic occlusion of distal coronaries", "Vasospasm induced by ergonovine"], "answer": "A", "answer_index": 0, "explanation": "Takotsubo cardiomyopathy involves catecholamine-mediated myocardial stunning, mimicking acute coronary syndrome without angiographic abnormalities. Dissection would show vessel irregularities on angiography. Myocarditis typically presents with inflammatory markers and different ventricular patterns.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a classic Takotsubo (stress) cardiomyopathy presentation: elderly patient, acute chest pain/hypotension mimicking ACS, non-obstructive coronaries on angiography, and characteristic apical ballooning on ventriculography. Key discriminating findings are the combination of ACS-like presentation with normal coronaries plus apical ballooning—pathognomonic for Takotsubo. Option A (catecholamine surge causing transient myocardial stunning) correctly identifies the established pathophysiology. Option B (SCAD) would show vessel irregularities/dissection flaps on angiography, explicitly excluded. Option C (myocarditis) typically shows diffuse/regional wall motion abnormalities, elevated inflammatory markers, and lacks the specific apical ballooning pattern. Option D (embolic occlusion) contradicts 'no obstructive disease' and would show filling defects. Option E (ergonovine vasospasm) is a provocation test scenario, not spontaneous presentation, and wouldn't explain apical ballooning. The stem provides sufficient discriminating details; the keyed answer aligns with current understanding of Takotsubo pathophysiology. Medical accuracy is excellent—catecholamine-mediated stunning is the accepted mechanism. No logical flaws or ambiguity. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic Takotsubo (stress) cardiomyopathy presentation: elderly patient, acute chest pain/hypotension mimicking ACS, non-obstructive coronaries on angiography, and characteristic apical ballooning on ventriculography. Key discriminating findings are the combination of ACS-like presentation with normal coronaries plus apical ballooning—pathognomonic for Takotsubo. Option A (catecholamine surge causing transient myocardial stunning) correctly identifies the established pathophysiology. Option B (SCAD) would show vessel irregularities/dissection flaps on angiography, explicitly excluded. Option C (myocarditis) typically shows diffuse/regional wall motion abnormalities, elevated inflammatory markers, and lacks the specific apical ballooning pattern. Option D (embolic occlusion) contradicts 'no obstructive disease' and would show filling defects. Option E (ergonovine vasospasm) is a provocation test scenario, not spontaneous presentation, and wouldn't explain apical ballooning. The stem provides sufficient discriminating details; the keyed answer aligns with current understanding of Takotsubo pathophysiology. Medical accuracy is excellent—catecholamine-mediated stunning is the accepted mechanism. No logical flaws or ambiguity. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-009", "question": "A 35-year-old pregnant woman at 28 weeks with antiphospholipid syndrome develops thrombocytopenia and elevated liver enzymes. Fetal monitoring shows growth restriction. What is the most appropriate management strategy?", "options": ["Low-dose aspirin and low-molecular-weight heparin continuation with close monitoring", "Immediate delivery to prevent maternal deterioration", "Plasmapheresis for antibody removal", "Intravenous immunoglobulin infusion", "Switch to unfractionated heparin"], "answer": "A", "answer_index": 0, "explanation": "In antiphospholipid syndrome during pregnancy, continuing low-dose aspirin and LMWH is standard to manage thrombotic risks and prevent complications like HELLP-like syndrome, with vigilant monitoring. Immediate delivery is premature at 28 weeks without severe features. IVIG is not first-line and reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 28-week pregnant woman with APS presenting with thrombocytopenia, elevated liver enzymes, and fetal growth restriction—features overlapping with HELLP syndrome or severe preeclampsia. Key stem clues: thrombocytopenia + elevated LFTs + FGR at 28 weeks in APS patient. The critical missing detail is severity assessment (platelet count, degree of LFT elevation, maternal symptoms, fetal status). Option A (continue aspirin/LMWH with monitoring) is reasonable if features are mild and stable. However, Option B (immediate delivery) becomes equally or more defensible if there are severe features (platelets <100k, AST/ALT >2x normal, severe FGR, abnormal fetal testing), as ACOG guidelines recommend delivery for severe preeclampsia/HELLP at ≥34 weeks, with consideration even earlier if maternal/fetal deterioration occurs. At 28 weeks with described complications, many clinicians would consider corticosteroids for fetal lung maturity followed by delivery within 24-48 hours if severe. The item is underspecified regarding severity, leading to multiple defensible answers. Medical accuracy: The keyed rationale oversimplifies—'premature at 28 weeks without severe features' assumes mild disease, but the stem doesn't specify this. Minimal fix: Add severity indicators (e.g., 'mild thrombocytopenia [platelets 120k], AST 80 U/L, stable fetal testing') to justify continued expectant management.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 28-week pregnant woman with APS presenting with thrombocytopenia, elevated liver enzymes, and fetal growth restriction—features overlapping with HELLP syndrome or severe preeclampsia. Key stem clues: thrombocytopenia + elevated LFTs + FGR at 28 weeks in APS patient. The critical missing detail is severity assessment (platelet count, degree of LFT elevation, maternal symptoms, fetal status). Option A (continue aspirin/LMWH with monitoring) is reasonable if features are mild and stable. However, Option B (immediate delivery) becomes equally or more defensible if there are severe features (platelets <100k, AST/ALT >2x normal, severe FGR, abnormal fetal testing), as ACOG guidelines recommend delivery for severe preeclampsia/HELLP at ≥34 weeks, with consideration even earlier if maternal/fetal deterioration occurs. At 28 weeks with described complications, many clinicians would consider corticosteroids for fetal lung maturity followed by delivery within 24-48 hours if severe. The item is underspecified regarding severity, leading to multiple defensible answers. Medical accuracy: The keyed rationale oversimplifies—'premature at 28 weeks without severe features' assumes mild disease, but the stem doesn't specify this. Minimal fix: Add severity indicators (e.g., 'mild thrombocytopenia [platelets 120k], AST 80 U/L, stable fetal testing') to justify continued expectant management.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed126", "question_id": "20251201T041413890Z_grok-4-0709_seed126-010", "question": "In the critical care unit, a 60-year-old patient with acute respiratory distress syndrome on mechanical ventilation develops refractory hypoxemia despite prone positioning. Extracorporeal membrane oxygenation is considered. What is the primary indication for venovenous ECMO in this scenario?", "options": ["PaO2/FiO2 ratio less than 80 with FiO2 greater than 90%", "Hypercapnia unresponsive to increased minute ventilation", "Right ventricular failure on echocardiography", "Sepsis-induced myocardial depression", "Barotrauma from high plateau pressures"], "answer": "A", "answer_index": 0, "explanation": "Venovenous ECMO is indicated for severe ARDS when PaO2/FiO2 <80 on FiO2 >90%, despite optimal ventilatory support, to provide gas exchange. Hypercapnia alone may be managed with permissive strategies or ECCO2R. Right ventricular failure would prompt venoarterial ECMO consideration instead.", "generator_model": "grok-4-0709", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 60-year-old with severe ARDS on mechanical ventilation with refractory hypoxemia despite prone positioning, asking for the primary indication for venovenous (VV) ECMO. Key discriminating findings: refractory hypoxemia in ARDS, already on advanced ventilatory support (prone positioning), considering VV-ECMO specifically. Option A (PaO2/FiO2 <80 with FiO2 >90%) correctly identifies the established threshold for severe refractory hypoxemia warranting VV-ECMO per ELSO and major trial criteria (EOLIA, CESAR). This represents failure of conventional ventilation with life-threatening gas exchange impairment. Option B (hypercapnia) is typically managed with permissive hypercapnia or ECCO2R, not primary VV-ECMO indication. Option C (RV failure) would indicate VA-ECMO for circulatory support, not VV-ECMO. Option D (septic cardiomyopathy) similarly requires VA-ECMO. Option E (barotrauma) is a complication but not a primary ECMO indication; lung-protective strategies would be adjusted first. The keyed answer aligns with current ECMO guidelines and critical care standards. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 60-year-old with severe ARDS on mechanical ventilation with refractory hypoxemia despite prone positioning, asking for the primary indication for venovenous (VV) ECMO. Key discriminating findings: refractory hypoxemia in ARDS, already on advanced ventilatory support (prone positioning), considering VV-ECMO specifically. Option A (PaO2/FiO2 <80 with FiO2 >90%) correctly identifies the established threshold for severe refractory hypoxemia warranting VV-ECMO per ELSO and major trial criteria (EOLIA, CESAR). This represents failure of conventional ventilation with life-threatening gas exchange impairment. Option B (hypercapnia) is typically managed with permissive hypercapnia or ECCO2R, not primary VV-ECMO indication. Option C (RV failure) would indicate VA-ECMO for circulatory support, not VV-ECMO. Option D (septic cardiomyopathy) similarly requires VA-ECMO. Option E (barotrauma) is a complication but not a primary ECMO indication; lung-protective strategies would be adjusted first. The keyed answer aligns with current ECMO guidelines and critical care standards. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]